It’s been refreshing to see colleagues and discuss the data at #ASCO2022 We are excited to see coverage #ASCODailyNews of the OS benefit for previously treated NSCLC with ramucirumab and pembrolizumab in S1800A ASCO dailynews.ascopubs.org/do/10.1200/ADN…

Very proud of my former fellow, Dr. Rakshit who presented data on hepatotoxicity from sotorasib following IO. Increased rates of grade 3 transaminase elevation if IO<3months from sotorasib #WCLC22

NOW we must change the #melanoma management guidelines across the world. #Neoadjuvant #immunotherapy better than adjuvant in resectable stage 3&4 melanoma SWOG1801 HR 0.58 p0.004 fir event-free survial